Experience of subcutaneous immunotherapy with mite and cedar allergen

DOI
  • Horiuchi Tatsuya
    Department of Otorhinolaryngology, Head and Neck Surgery, Yamanashi University Graduate School of Medicine
  • Sakamoto Kaname
    Department of Otorhinolaryngology, Head and Neck Surgery, Yamanashi University Graduate School of Medicine
  • Yonaga Takaaki
    Department of Otorhinolaryngology, Head and Neck Surgery, Yamanashi University Graduate School of Medicine
  • Igarashi Satoshi
    Department of Otorhinolaryngology, Head and Neck Surgery, Yamanashi University Graduate School of Medicine
  • Tanaka Shota
    Department of Otorhinolaryngology, Head and Neck Surgery, Yamanashi University Graduate School of Medicine
  • Kamijo Atsushi
    Department of Otorhinolaryngology/Allergy Center, Saitama Medical University
  • Sakurai Daijyu
    Department of Otorhinolaryngology, Head and Neck Surgery, Yamanashi University Graduate School of Medicine
  • Masuyama Keisuke
    Department of Otorhinolaryngology, Suwa Central Hospital
  • Matsuoka Tomokazu
    Department of Otorhinolaryngology, Head and Neck Surgery, Yamanashi University Graduate School of Medicine

Bibliographic Information

Other Title
  • 当科におけるダニおよびスギ花粉アレルゲンエキスによる皮下免疫療法の安全性の検討

Search this article

Abstract

<p>Background: Subcutaneous immunotherapy (SCIT) has been among the most effective treatments for allergic rhinitis for over a century. However, systemic reactions remain a serious problem with SCIT; they still occur in approximately 0.2% of injections. Recently, sublingual immunotherapy has been established as a safer treatment than SCIT. However, some patients require SCIT due to disease or compliance related issues. We investigated patients who underwent SCIT at our hospital and examined its safety.</p><p>Subjects: Patients who underwent SCIT using a mite and/or Japanese cedar pollen allergen extract in our department were investigated in this study.</p><p>Results: In total, 44 patients between 5 and 58 years of age underwent SCIT, and 9 (20.5%) experienced systemic reactions. Two patients treated using only mite allergen and seven using Japanese cedar pollen and mite allergens experienced systemic reactions. There was a significantly higher frequency of systemic reactions among patients in the dose-increase phase than in the maintenance phase (p<0.01). All patients who had systemic reactions exhibited whole skin eruption. All cases were properly treated, and no serious problems occurred.</p><p>Discussion: No statistically significant difference was observed in the risk of systemic reactions between SCIT using mite and Japanese cedar pollen allergens.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top